Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer

• Published in: JCO precision oncology Vol. 8; p. e2300274
• Main Authors: Lenis, Andrew T, Whiting, Karissa, Ravichandran, Vignesh, Tallman, Jacob E, Alam, Syed M, Chu, Carissa E, Jesus Escano, Manual De, Bochner, Emily, Katims, Andrew, Reisz, Peter A, Truong, Hong, Clinton, Timothy N, Telis, Leon, Dason, Shawn, McPherson, Victor, Teo, Min Yuen, Funt, Samuel, Aggen, David, Goh, Alvin C, Donahue, Timothy F, Cha, Eugene K, Donat, S Machele, Herr, Harry W, Dalbagni, Guido, Schultz, Nikolaus, Berger, Michael F, Bajorin, Dean F, Rosenberg, Jonathan E, Bochner, Bernard H, Ostrovnaya, Irina, Al-Ahmadie, Hikmat, Solit, David B, Iyer, Gopa, Pietzak, Eugene J
• Format: Journal Article
• Language: English
• Published: United States 01.04.2024
• Subjects: Aged; Cisplatin - therapeutic use; Cystectomy; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Drug Resistance, Neoplasm - genetics; Female; Gemcitabine; Genomics; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - genetics; Urinary Bladder Neoplasms - pathology
• ISSN: 2473-4284
• DOI: 10.1200/PO.23.00274

Patients with residual invasive bladder cancer after neoadjuvant chemotherapy (NAC) and radical cystectomy have a poor prognosis. Data on adjuvant therapy for these patients are conflicting. We sought to evaluate the natural history and genomic landscape of chemotherapy-resistant bladder cancer to inform patient management and clinical trials. Data were collected on patients with clinically localized muscle-invasive urothelial bladder cancer treated with NAC and cystectomy at our institution between May 15, 2001, and August 15, 2019, and completed four cycles of gemcitabine and cisplatin NAC, excluding those treated with adjuvant therapies. Survival was estimated using the Kaplan-Meier method, and multivariable Cox proportional hazards models were used to identify predictors of recurrence-free survival (RFS). Genomic alterations were identified in targeted exome sequencing (Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets) data from post-NAC specimens from a subset of patients. Lymphovascular invasion (LVI) was the strongest predictor of RFS (hazard ratio, 2.15 [95% CI, 1.37 to 3.39]) on multivariable analysis. Patients with ypT2N0 disease without LVI had a significantly prolonged RFS compared with those with LVI (70% RFS at 5 years). Lymph node yield did not affect RFS. Among patients with sequencing data (n = 101), chemotherapy-resistant tumors had fewer alterations in DNA damage response genes compared with tumors from a publicly available chemotherapy-naïve cohort (15% 29%; = .021). Alterations in were associated with shorter RFS. alterations were associated with LVI. Potentially actionable alterations were identified in more than 75% of tumors. Although chemotherapy-resistant bladder cancer generally portends a poor prognosis, patients with organ-confined disease without LVI may be candidates for close observation without adjuvant therapy. The genomic landscape of chemotherapy-resistant tumors is similar to chemotherapy-naïve tumors. Therapeutic opportunities exist for targeted therapies as adjuvant treatment in chemotherapy-resistant disease.